SCHEMBL6735213

SCHEMBL6735213

CS(=O)(=O)c1c(F)cc(C2=C(c3ccc(C(F)(F)F)cc3)C=CC2)cc1F

nearest known ligand 0.42

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 10/20 0.42
KIF11 P52732 8/20 0.39
ALOX5AP P20292 2/20 0.36
FEN1 P39748 2/20 0.36
PTGS1 P23219 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6735444 0.87 PTGS2 (0.40) PTGS2PTGS1
SCHEMBL6788149 0.87 KDM4E (0.39) PTGS2KIF11
SCHEMBL6729355 0.86 PTGS2 (0.41) PTGS2KIF11PTGS1
SCHEMBL6732637 0.86 PTGS2 (0.35) PTGS2KIF11PTGS1
SCHEMBL6734381 0.85 PTGS2 (0.38) PTGS2PTGS1
SCHEMBL6728950 0.84 PTGS2 (0.43) PTGS2KIF11PTGS1
SCHEMBL6737041 0.84 PTGS2 (0.34) PTGS2PTGS1
SCHEMBL6735615 0.84 PTGS2 (0.45) PTGS2PTGS1
SCHEMBL6736301 0.83 PTGS2 (0.40) PTGS2KIF11PTGS1
SCHEMBL6729895 0.83 KIF11 (0.42) PTGS2KIF11PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885KIF11 4765/4885ALOX5AP 603/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885KIF11 4765/4885ALOX5AP 603/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885KIF11 4765/4885ALOX5AP 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.